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Orangeburg, New York; Thurmont, Maryland; and Indianola, PennsylvaniaObjectives This study sought to evaluate vascular drug uptake, distribution and response of second-
generation paclitaxel coated balloon (PCB) (Cotavance, MEDRAD Interventional, Indianola, Pennsylvania)
and compare it with ﬁrst-generation technology, containing identical excipient and drug concentration.
Background Original PCB technologies displayed a heterogeneous deposition of crystalline paclitaxel-
iopromide inside the balloon folds, whereas second-generation PCBs consisted of more homogeneous,
circumferential coatings.
Methods Paclitaxel tissue uptake was assessed in 20 iliofemoral arteries of a domestic swine. Vascular
healing responsewasassessed in the familial hypercholesterolemicmodelof iliofemoral in-stent restenosis.
Three weeks after bare-metal stent implantation, vascular segments were randomly revascularized with
ﬁrst-generation PCBs (n¼ 6), second-generation PCBs (n¼ 6), or plain balloon angioplasty (PBA) (n ¼ 6).
At 28 days, angiographic and histological evaluation was performed in all treated segments.
Results One-hour paclitaxel tissue uptake was 42% higher in the second-generation PCBs (p ¼ 0.03)
and resulted in more homogeneous segment-to-segment distribution compared with ﬁrst-generation
PCBs. Both angiography (percentage of diameter stenosis: second-generation 11.5  11% vs. ﬁrst-
generation 21.9  11% vs. PBA 46.5  10%; p < 0.01) and histology (percentage of area stenosis:
second-generation 50.5  7% vs. ﬁrst-generation 54.8  18% vs. PBA 78.2  9%; p < 0.01) showed
a decrease in neointimal proliferation in both PCB groups. Histological variance of the percentage of
area stenosis was lower in second-generation compared with ﬁrst-generation PCBs (51.7 vs. 328.3;
p ¼ 0.05). The presence of peristrut ﬁbrin deposits (0.5 vs. 2.4; p < 0.01) and medial smooth muscle cell
loss (0 vs. 1.7; p < 0.01) were lower in the second-generation compared with ﬁrst-generation PCBs.
Conclusions In the experimental setting, second-generation PCB showed a comparable efﬁcacy
proﬁle and more favorable vascular healing response when compared to ﬁrst-generation PCB. The
clinical implications of these ﬁndings require further investigation. (J Am Coll Cardiol Intv 2013;
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884Paclitaxel-coated balloon (PCB) technologies have been with xylazine and tiletamine HCl/zolazepam HCl and
clinically introduced as an alternative therapy to drug-eluting
stents and plain balloon angioplasty (PBA) for treatment of
coronary in-stent restenosis (ISR) (1,2) and de novo pe-
ripheral artery disease (3,4). After these promising results,
further use of PCBs has been extended to other applications
such as de novo coronary lesions (5–9). First-generation
coatings, although clinically effective, used manual coating
techniques and deposited the drug preferentially within the
balloon folds, resulting in nonhomogeneous drug surface
distribution. In the past several years, advancements in
coating techniques have yielded more reproducible circum-
ferential coatings with higher dosing precision and uniform
drug-excipient distribution along the balloon surface. In this
series of studies, we compared the pharmacokinetic proﬁle of
the original Paccocath technology (ﬁrst-generation PCB)Abbreviations
and Acronyms
%AS = percentage of area
stenosis
%DS = percentage of
diameter stenosis
EEL = external elastic lamina
FHS = familial
hypercholesterolemic swine
IEL = internal elastic lamina
ISR = in-stent restenosis
MLD = minimal lumen
diameter




QVA = quantitative vascular
angiography




second-generation PCB in the
iliofemoral territory of a healthy
swine. In addition, we evaluated
the vascular healing response of
the same devices in the iliofe-




Device description. The ﬁrst-
generation PCB used in this
study (Paccocath technology,
Bayer Pharma AG/MEDRAD
Inc.) was coated using a proprie-
tary dipping process containing
a paclitaxel-iopromide formula-
tion (3 mg/mm2) deposited pref-erentially in the folds of the balloon. The second-generation
PCB used in this study (Cotavance technology, Bayer Pharma
AG/MEDRAD Inc.) used a similar paclitaxel-iopromide
formulation and concentration. Precise microsyringe cir-
cumferential deposition was used, allowing a higher degree of
coating uniformity and precision of dosing (data on ﬁle at
MEDRAD). All balloons and self-expandable nitinol stents
used for model creation were 5 to 7  20 mm.
Experimental design and procedures. Figure 1 describes the
study designs and groups. All experiments were approved
by the Institutional Animal Care and Use Committee.
Animals received standard of care outlined in accordance
with the USDA Animal Welfare Act and the Guide for Care
and Use of Laboratory Animals (9). Each animal received
dual antiplatelet therapy 1 day before the procedure and
continued until termination. General anesthesia was inducedmaintained with inhaled 1% to 3% isoﬂurane. Carotid artery
access was obtained via cutdown. Before catheterization,
heparin (5,000 to 10,000 U) was administered to maintain
activated clotting time >250 s. Nitroglycerin was adminis-
tered intra-arterially to prevent and relieve vasospasm.
Tissue transfer study. A total of 20 iliofemoral arteries (5
domestic swine) were included in the paclitaxel tissue transfer
study. Test devices (12 ﬁrst-generation vs. 8 second-genera-
tion) were inﬂated based on quantitative vascular angiography
(QVA)–derived vessel reference diameters to achieve
a balloon-to-artery ratio of 1.2:1.0 for 30 s. One hour after the
procedure, animals were euthanized, and the treated vessels
were harvested for paclitaxel analysis. Tissues were cut into 3
sections (proximal, medial, and distal), weighed, and then
homogenized in a phosphate-buffered solution. The
homogenate was labeled with an internal standard, extracted,
and evaporated to dryness. The reconstituted sample was
analyzed by reverse-phase high-performance liquid chroma-
tographywith tandemmass spectrometry detection. The assay
range for paclitaxel in porcine tissue was 0.3 to 500 ng/g using
a nominal sample size of 100 mg of tissue.
Vascular healing response study. IN-STENT RESTENOSIS
DEVELOPMENT. The FHS model (10–13) has been used and
validated by our laboratory for the evaluation of device efﬁ-
cacy in the iliofemoral territory in de novo (14) and ISR (15)
settings. In this study, a total of 5 FHS were included in the
vascular healing response study. The protocol for the devel-
opment of ISR in the peripheral vasculature model of FHS
has been described previously (16), and a detailed description
of the method is provided in the Online Appendix. A total of
20 iliofemoral arteries (4 in each animal) were screened using
QVA to select the appropriate segment for treatment. Two
sites were excluded due to inappropriate vessel diameters. All
vessels were injured with an oversized balloon followed by
self-expandable bare-metal stent implantation (day 0). After
21 days, all stented segments were randomly treated with
ﬁrst-generation PCB (n ¼ 6), second-generation PCB
(n ¼ 6), or PBA (n ¼ 6). Four weeks later (day 49), terminal
angiography was performed, and arterial tissue was sent for
histological evaluation.
ANGIOGRAPHIC ANALYSIS. QVA was performed at all time
points using QAngio-XA Software version 7.1.14.0 (Medis,
Medical Imaging Systems, Leiden, the Netherlands). The
following parameters were measured using the guiding
catheter as a standard for calibration: minimal lumen
diameter (MLD) within the treated segments, reference
vessel diameter (RVD) measured at the proximal and distal
portions of the treated sites, and the balloon and stent-to-
artery ratio. The percentage of diameter stenosis (%DS) pre-
procedure (day 21) and follow-up (day 49) were calculated
as: (1  [MLD/RVD])  100% and the late loss was
calculated as (MLD at follow-up MLD at post-inﬂation).
Figure 1. Flowchart of the Study Designs
BMS ¼ bare-metal stent(s); DS ¼ domestic swine; FHS ¼ familial hypercholesterolemic swine; Gen ¼ generation; ISR ¼ in-stent restenosis; PBA ¼ plain balloon
angioplasty; PCB ¼ paclitaxel-coated balloon.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 8 , 2 0 1 3 Buszman et al.
A U G U S T 2 0 1 3 : 8 8 3 – 9 0 First- vs. Second-Generation Paclitaxel-Coated Balloons
885HISTOLOGICAL ANALYSIS. The histological analysis was
conducted by an independent pathology laboratory (Alizée
Pathology, LLC, Thurmont, Maryland). After terminal
imaging, animals were euthanized, and all treated vessels
harvested and immersed in 10% neutral buffered formalin.
All vessels were ﬁrst embedded in methylmethacrylate and
then cut in 40- to 50-mm sections obtained from the
proximal, mid, and distal portions of each stented segment.
These sections were stained with hematoxylin and eosin and
elastic trichrome. The cross-sectional areas (external elastic
lamina [EEL], internal elastic lamina [IEL], and lumen
area) of each section were measured and used to calculate
vessel layer areas with the following formulas: media ¼
EEL  IEL; neointima ¼ IEL  lumen; the percentage of
area stenosis (%AS) ¼ (1  [lumen area/IEL area])  100.
The criteria of Schwartz et al. (17) and Kornowski et al. (18)
were used to evaluate the amount of injury and inﬂamma-
tion. Detailed description of qualitative analysis is provided
in the Online Appendix.
Statistical analysis. Normally distributed parametric data are
expressed as average and SD or variance, while skewed as
median and interquartile range. For continuous and ordinal
data, the Levene equal variance and Shapiro-Wilk normality
tests were initially performed. When equal variance and
normality were observed, 1-way analysis of variance with
Holm-Sidak post-analysis of variance or Student t test were
used to test for differences in variables between balloon
types. When either the equal variance test or normality test
failed, the Kruskal-Wallis (with Dunn’s method for post
hoc) or Mann-Whitney U test was used. A value of p  0.05was considered statistically signiﬁcant. An F test of equality
of variances was used to assess neointimal homogeneity.Results
Paclitaxel tissue uptake study. Arterial tissue was harvested
1 h after PCB dilation. The pharmacokinetic proﬁle of all
tested groups based on concentration is shown in Figure 2.
The baseline overall vessel size was comparable in both
groups (data not shown). The 1-h total paclitaxel tissue
uptake was 42% higher in the second-generation PCB
compared with the ﬁrst-generation PCB (p ¼ 0.03).
Segment-to-segment analysis revealed that delivery of
paclitaxel from the second-generation PCB resulted in
a higher paclitaxel uptake in the proximal and distal portions
of the vessel compared with the ﬁrst-generation PCB
(Fig. 2), resulting in more uniform distribution.
Vascular healing response to paclitaxel transfer. ANGIO-
GRAPHIC ANALYSIS. The angiographic analysis is summa-
rized in Table 1. All angiographic variables were comparable
before initial injury. At the time of PCB treatment (21
days), the mean baseline %DS was similar in all groups. The
mean ﬁnal balloon inﬂation diameters were also similar,
leading to a similar angiographic acute gain post-vessel
treatment. At last follow-up, the %DS was signiﬁcantly
lower in both PCB groups compared with PBA (second-
generation PCB: 75% reduction and ﬁrst-generation PCB:
52% reduction). Similarly, there was a statistically signiﬁcant
3- to 4-fold reduction in angiographic late lumen loss in
Figure 2. One-Hour Tissue Transfer Study
Paclitaxel acute uptake is higher and distribution more uniform along stented segments after drug delivery via second-generation PCB. Abbreviations as in Figure 1.
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886both PCB groups compared with PBA. There were no
statistical differences in any of the angiographic endpoints
between ﬁrst-generation and second-generation PCBs.HISTOLOGICAL ANALYSIS. A summary of the histological
ﬁndings is shown in Table 2. All variables representing
neointimal hyperplasia such as neointimal thickness, neo-
intimal area, and %AS were comparable between both
PCB groups and signiﬁcantly lower than PBA (Fig. 3).
Neointimal homogeneity deﬁned as the variance of %AS
was signiﬁcantly higher in the ﬁrst-generation PCB
compared with the second-generation PCB (328.3 vs. 51.7;
p ¼ 0.05). Similarly, the analysis of %AS among sections
showed Gaussian-like distribution in the second-generation
PCB (p ¼ 0.59) and skewed in ﬁrst-generation PCB
(p ¼ 0.03) (Fig. 4). Signiﬁcant restenosis (%AS >75) did
not occur in any of the second-generation PCBs, whereas it
was found in 1 ﬁrst-generation PCB stent and in 3 in the
PBA control group. There was a tendency toward positive
vessel remodeling in the second-generation PCB expressed
by higher EEL and IEL areas.
The healing and biocompatibility proﬁle of all tested
devices is presented in Figure 5. The peristrut inﬂammation
scores were lower (<1.0) in both PCB groups compared
with PBA (>2.0). Neointimal maturity score was highest in
the second-generation PCB and PBA groups compared
with the ﬁrst-generation PCB. In the medial layer, smooth
muscle cell loss was not observed in the second-generation
PCB and PBA groups, whereas evidence of acellularity was
present in ﬁrst-generation PCB. Finally, peristrut ﬁbrin
deposits were more commonly seen in the ﬁrst-generation
PCB compared with the second-generation PCB and PBAcontrol groups. Representative pictures of stent cross
sections of all 3 groups are presented in Figure 6.Discussion
First-generation PCB coatings used manual coating tech-
niques and deposited the drug preferentially within the
balloon folds, contributing in part to nonhomogeneous drug
surface distribution. Early experimental studies suggested
this early-generation coating, although clinically effective,
displayed inconsistent results in drug delivery and healing
response (19–22). In the past several years, advancements in
coating techniques resulted in more reproducible circum-
ferential coatings with higher dosing precision and uniform
drug-excipient distribution along the balloon surface. In
this series of studies, we compared the pharmacokinetic
proﬁle of the original Paccocath technology (ﬁrst-generation
PCB) with the second-generation PCB in the iliofemoral
territory of healthy swine. In addition, we evaluated the
vascular healing response of the same devices in the same
vascular territory in the FHS model of ISR.
The use of healthy arteries for evaluating uptake and
retention of local drug delivery agents is a well-established
model (20,22,23). Although limited by the absence of un-
derlying disease, the anatomic and physiological resemblance
to humans has proved this model to be effective in estimating
the pharmacokinetic behavior of different drug-eluting de-
vices (20,22,24,25). On the other hand, predicting clinical
efﬁcacy in nondiseased animal models has proved to be
challenging (23). In this study, we used the FHS model of
iliofemoral ISR to assess the vascular response to both PCB
coating technologies (16). Previous studies have shown the






(n ¼ 6) p Value
Injury (day 0)
RVD 4.28  0.4 4.24  0.3 4.12  0.7 0.9
BAR 1.23  0.02 1.26  0.02 1.24  0.05 0.54
Post-stent
MLD
4.96  0.5 4.8  0.1 4.6  0.2 0.3
Pre-treatment (day 21)
RVD 4.18  0.5 4.15  0.4 4.04  0.8 0.91
MLD 3.42  0.5 3.28  0.5 2.97  0.5 0.28
%DS 17.9  10.2 20.1  15.6 25.9  9.6 0.51
After treatment
RVD 3.85  0.4 3.80  0.4 3.71  0.6 0.88
MLD 3.53  0.8 3.74  0.3 3.46  0.5 0.69
Balloon diameter 4.68  0.5 4.51  0.4 4.53  0.5 0.77
Acute gain 0.5  0.11 0.46  0.6 0.50  0.4 0.36
%DS 7.30  23.3 0.95  11.0 6.18  8.7 0.76
Follow-up (day 49)
RVD 4.21  0.3 4.33  0.4 4.22  0.7 0.89
MLD 3.72  0.5* 3.39  0.6* 2.24  0.5 <0.01
%DS 11.5  11.0* 21.9  11.1* 46.5  10.9 <0.01
Late loss 0.41  0.9* 0.35  0.6* 1.22  0.6 <0.01
Values are mean  SD. *p < 0.05 versus plain balloon angioplasty.
BAR ¼ balloon-to-artery ratio; %DS ¼ percentage of diameter stenosis; MLD ¼ minimal lumen diameter; PCB ¼ paclitaxel-coated balloon; PBA ¼
plain balloon angioplasty; RVD ¼ reference vessel diameter.
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887utility of this model in the evaluation of efﬁcacy of drug-
delivery devices in the novo (14) and ISR (15) settings. These
studies have shown that the combination of the intrinsic
metabolic defect of the FHS and vessel wall injury is sufﬁ-
cient to demonstrate differences in efﬁcacy after the use of
different PCB technologies compared with PBA (17).
The tissue uptake study revealed that the second-
generation PCB had slightly higher paclitaxel concentration
and a more uniform segment-to-segment distribution along
the artery compared with the ﬁrst-generation PCB. In the
vascular healing response study, the efﬁcacy of paclitaxel in
reducing neointimal proliferation was comparable in both
PCB groups and signiﬁcantly reduced compared with PBA




EEL area, mm2 27.8 (25.0–30.0)*
IEL area, mm2 25.0  1.7*y
Lumen area, mm2 12.4  1.9*y
Medial area, mm2 2.4 (1.7–2.7)
Neointimal area, mm2 12.8  2.2
Neointimal thickness, mm 854.4  161.0y
Area of stenosis, % 50.5  7.0%y
Values are mean (range) or mean  SD. *p < 0.05 vs. ﬁrst-generation PCB.
EEL ¼ external elastic lamina; IEL ¼ internal elastic lamina; other abbrevistented segment was higher in the ﬁrst-generation PCB
compared with the second-generation PCB (within a 30% to
60% range of %AS) (Fig. 4). Our results support the notion
that more uniform and reproducible balloon coating results in
more homogeneous drug distribution along the treated site.
This is an important ﬁnding because the variation in tissue
concentration of paclitaxel appears to inﬂuence the overall
healing response after PCB treatment. In addition, second-
generation PCB resulted in a more favorable biological
response, showing lower ﬁbrin deposition and neointimal
and medial smooth muscle cell loss and the presence of more
mature neointimal layers. Our data also support previous
studies reporting the potential deleterious vascular effects of




(n ¼ 6) p Value
22.7 (21.0–25.0) 24.3 (21.0–28.0) 0.04
19.6  1.6 18.9  1.6 0.02
8.8  3.7y 4.0  1.4 <0.01
3.36 (2.5–3.9) 4.79 (2.0–8.0) 0.37
10.7  3.5 14.9  2.8 0.07
864.3  394.0y 1,354.8  284.0 0.01
54.8  18.0%y 78.2  10.0% 0.01
yp < 0.05 vs. PBA.
ations as in Table 1.
Figure 3. Percentage of Area Stenosis on Histological Analysis
The efﬁcacy of paclitaxel in reducing neointimal proliferation was comparable in both PCB groups and signiﬁcantly reduced compared with PBA controls.
Abbreviations as in Figure 1.
Buszman et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 8 , 2 0 1 3
First- vs. Second-Generation Paclitaxel-Coated Balloons A U G U S T 2 0 1 3 : 8 8 3 – 9 0
888To date, only 1 study directly compared the vascular effects
of 2 different PCBs (26). This study, however, differed
signiﬁcantly with regard to the excipient and balloon tech-
nology used (iopromide vs. roughened surface). Although new
PCB developments are under investigation (27,28), the inﬂu-
ence on vascular response and pharmacokinetics has not been
compared with those of the original Paccocath formulation.
Therefore, to the best of our knowledge, our study is the ﬁrst to
provide a head-to-head comparison of ﬁrst- and second-
generation PCB technologies. In addition, because both PCBs
used in this study shared identical coating formulations andFigure 4. Histograms Representing Neointimal Distribution According to the Per
Normal and within a range of 30% to 60% area stenosis, neointimal distribution was
p ¼ 0.03 and p ¼ 0.59).drug concentrations, the importance of the coating methods
and techniqueswas distinguished and validatedbyourﬁndings.
The clinical implications of these ﬁndings are impor-
tant. First, as PCB technologies evolve and the tissue
delivery and distribution of paclitaxel become more
consistent, the introduction of this technology into clinical
practice becomes more appealing. In addition, because
these new-generation coatings appear to induce lower
degrees of delayed healing, there is a potential to expand
the use of this technology to a broader range of appli-
cations (6,8). This is particularly important in the settingcentage of Area Stenosis in Stented Cross Sections
observed in second- (A) and skewed in ﬁrst-generation PCBs (B) (Shapiro-Wilk,
Figure 5. Healing and Biocompatibility Proﬁle
Qualitative histopathological analysis representing healing (A) and biocompatibility (B). Second-generation paclitaxel-coated balloon resulted in a more favorable
biological response showing lower ﬁbrin deposition and neointimal and medial smooth muscle cell loss and the presence of mature neointimal layers. Abbreviations as
in Figure 1.
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889of adjunctive bare-metal stent use in which the synergistic
use of PCB in the coronary territory remains controversial
(8,29).
Study limitations. First, although a disease animal model
was used, the lack of an atherosclerotic plaque componentFigure 6. Representations of Vessel Sections of All Groups
Abbreviations as in Figure 1.neglects the impact of tissue characteristics on drug
uptake and retention. Second, although long-term pac-
litaxel retention was not tested in this study, the retention
up to 6 months has already been reported for both PCB
groups (30).
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890Conclusions
In the experimental setting, second-generation PCB tech-
nologies displayed a similar degree of efﬁcacy compared with
the original ﬁrst-generation PCB formulation. However,
paclitaxel delivery was more uniform throughout the vessel
length and resulted in more favorable vascular tissue proﬁle.
The clinical implications of these ﬁndings deserve further
investigation in human clinical trials.
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